Article Details
Retrieved on: 2018-05-06 20:31:18
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Celgene's <b>stock</b> performance so far this year has been dismal due primarily to a big setback in late February with the Food and Drug Administration rejecting its regulatory filing for ozanimod in treating multiple sclerosis (MS). This rejection was viewed by many as an unforced error by Celgene. Morgan ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here